AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
ethotoin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiepileptics, hydantoin derivatives | 1088 | 86-35-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2.50 | g | O |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K21,MAP3K7,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SIK2,SIK3,STK33,TEK | 29 | |||
| kinase-selectivity-class | AXL,BRAF,CAMK2D,CDK9,GRK2,MAPK7,SIK2,STK33,TEK | 9 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 22, 1957 | FDA | RECORDATI RARE |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N03AB01 | NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Hydantoin derivatives |
| FDA PE | N0000008486 | Decreased Central Nervous System Disorganized Electrical Activity |
| MeSH PA | D000927 | Anticonvulsants |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D026941 | Sodium Channel Blockers |
| MeSH PA | D049990 | Membrane Transport Modulators |
| MeSH PA | D061567 | Voltage-Gated Sodium Channel Blockers |
| CHEBI has role | CHEBI:35623 | anticonvulsant |
| FDA EPC | N0000175753 | Anti-epileptic Agent |
Related Drugs by ATC class:
N03AB Hydantoin derivatives 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Tonic-clonic epilepsy | indication | 352818000 | DOID:7725 |
| Epilepsy characterized by intractable complex partial seizures | indication | 442481002 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Mood swings | contraindication | 18963009 | |
| Lymphadenopathy | contraindication | 30746006 | |
| Depressive disorder | contraindication | 35489007 | |
| Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
| Megaloblastic anemia due to folate deficiency | contraindication | 85649008 | DOID:14026 |
| Disease of blood AND/OR blood-forming organ | contraindication | 191124002 | DOID:74 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Pregnancy, function | contraindication | 289908002 | |
| Porphyria | contraindication | 418470004 | |
| Fever greater than 100.4 Fahrenheit | contraindication | 426000000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.69 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium channel alpha subunit | Ion channel | BLOCKER | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018735 | VUID |
| N0000147040 | NUI |
| D00708 | KEGG_DRUG |
| 4018735 | VANDF |
| C0015046 | UMLSCUI |
| CHEBI:4888 | CHEBI |
| CHEMBL1095 | ChEMBL_ID |
| DB00754 | DRUGBANK_ID |
| 3292 | PUBCHEM_CID |
| C084606 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7183 | IUPHAR_LIGAND_ID |
| 660 | INN_ID |
| 46QG38NC4U | UNII |
| 204319 | RXNORM |
| 2970 | MMSL |
| 4702 | MMSL |
| d00942 | MMSL |
| 001620 | NDDF |
| 371384002 | SNOMEDCT_US |
| 64463006 | SNOMEDCT_US |
| 46QG38NC4U | INXIGHT DRUGS |
Pharmaceutical products:
None